Values First Advisors Inc. Purchases Shares of 420 Repligen Co. (NASDAQ:RGEN)

Values First Advisors Inc. acquired a new position in shares of Repligen Co. (NASDAQ:RGEN) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 420 shares of the biotechnology company’s stock, valued at approximately $62,000.

A number of other large investors have also recently made changes to their positions in the stock. Andra AP fonden acquired a new stake in Repligen during the 2nd quarter worth about $25,000. International Assets Investment Management LLC acquired a new stake in shares of Repligen during the second quarter worth about $33,000. UMB Bank n.a. boosted its position in Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 130 shares during the last quarter. Lazard Asset Management LLC increased its holdings in Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after buying an additional 136 shares during the period. Finally, Blue Trust Inc. raised its position in Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after buying an additional 127 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Up 0.2 %

Repligen stock opened at $135.45 on Friday. Repligen Co. has a 12 month low of $110.45 and a 12 month high of $211.13. The stock has a market capitalization of $7.59 billion, a PE ratio of -3,385.40, a price-to-earnings-growth ratio of 4.16 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. The business has a 50 day simple moving average of $143.45 and a 200-day simple moving average of $147.28.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The company had revenue of $154.07 million during the quarter, compared to analysts’ expectations of $154.11 million. During the same period in the prior year, the business posted $0.53 earnings per share. The firm’s revenue for the quarter was down 3.2% on a year-over-year basis. On average, analysts anticipate that Repligen Co. will post 1.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Benchmark reiterated a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Stephens reiterated an “overweight” rating and set a $170.00 price objective on shares of Repligen in a research note on Tuesday, July 30th. Royal Bank of Canada restated an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Wells Fargo & Company assumed coverage on Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price target for the company. Finally, UBS Group lowered their price objective on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $190.25.

Insider Buying and Selling at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the transaction, the vice president now directly owns 19,261 shares of the company’s stock, valued at $3,190,969.87. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.